ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 885

48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin

David Wofsy1, David A. Isenberg2, Frédéric A. Houssiau3, Mary Anne Dooley4, Neil Solomons5 and Simrat Randhawa6, 1Rheumatology, UCSF, San Francisco, CA, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 4UNC Kidney Centre, Chapel Hill, NC, 5Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 6Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Clinical research, Clinical Response, clinical trials, Lupus nephritis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the need for therapeutic drug monitoring.

VCS has completed testing in a global phase II trial, AURA, in patients with active lupus nephritis (LN).  In AURA, two doses of VCS (23.7mg BID, 39.5mg BID) were evaluated vs placebo in a double blind RCT when added on top of MMF (2g/ day) and a stringent steroid taper.

Methods:

The primary endpoint was 24-week complete remission (CR). However, blinding and randomization were maintained through 48 weeks permitting further efficacy assessments at 48 weeks.  CR required a confirmed UPCR of <0.5 mg/mg, eGFR >60 ml/min without a decrease of >20% from baseline, low-dose steroids for at least 8 weeks prior to the endpoint assessment and no administration of rescue medications.

Results:

Previously reported 24-week data showed a statistically significant CR improvement in patients receiving low dose VCS vs control (32.6% vs. 19.3%; OR: 2.03, p=0.045) and 27.3% in high dose VCS (p=NS). Furthermore, at 24 weeks both doses of VCS demonstrated statistical superiority over control in partial response (PR, 50% reduction in proteinuria from baseline) time to CR and time to PR.  VCS treatment effect increased at 48 weeks with 49.4% low-dose (OR 3.21, p<.001) and 39.8 % high dose (OR 2.1, p= .026) VCS patients achieving CR vs 29.6% of control patients.   Additionally, all low dose VCS patients in CR at 24 weeks remained in CR at 48 weeks. More AEs (84% control, 96% high, 91% low) and SAEs (19% control, 25% high, 28% low) were observed in both VCS arms compared to control. There were 13 deaths (low dose 10, high dose 2, control 1).  All deaths were considered unrelated to VCS treatment by investigators and were consistent with cause seen in other LN studies.  Eleven of thirteen deaths were clustered in sites with compromised access to standard of care and which disproportionately recruited to the low dose VCS arm. Following completion of study treatment, 3 control arm patients died while one developed a malignancy.  No additional deaths were reported in the low dose VCS arm following 24 weeks.

We now present a 48-week CR subgroup analysis based on ethnicity, sex and age.

Table 1: 48-week complete remission ethnic, sex and age subgroups

Subgroup

Low dose CR%, (OR)

High dose CR% (OR)

Control CR %

N

White

56.7 (3.64)

50 (2.82)

26.2

108

Asian Indian subcontinent

59.1 (2.95)

40 (1.35)

33.3

60

Asian other

40 (2.43)

29.2 (1.47)

22.2

72

Other

28.6 (>99)

25 (>99)

0

25

 

 

 

 

 

Female

51.3 (3.87)

38.3 (2.2)

21.9

230

Male

38.5 (1.19)

57.1 (2.63)

33.3

35

Age ≤30

44.2 (2.17)

39.2 (1.7)

27

140

Age ≥30

56.8 (4.82)

40.5 (2.5)

21.6

125

Conclusion:

48-week subgroup analysis demonstrates sustained VCS treatment effect that was consistent across subgroups.  AURA was not powered to show statistical significance in these subgroups; however, odds ratios strongly favored low and high dose VCS across these 8 subgroups. Further data regarding VCS treatment effect in subgroups of patients with active LN will is currently being generated in the phase III AURORA trial.

 


Disclosure: D. Wofsy, None; D. A. Isenberg, EMD Serono, Inc, 5; F. A. Houssiau, None; M. A. Dooley, None; N. Solomons, Aurinia Pharmaceutical, 3; S. Randhawa, Aurinia Pharmaceuticals, 3.

To cite this abstract in AMA style:

Wofsy D, Isenberg DA, Houssiau FA, Dooley MA, Solomons N, Randhawa S. 48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/48-week-complete-remission-by-ethnic-sex-and-age-subgroups-in-patients-with-active-lupus-nephritis-treated-with-voclosporin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/48-week-complete-remission-by-ethnic-sex-and-age-subgroups-in-patients-with-active-lupus-nephritis-treated-with-voclosporin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology